Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Microcurrent Stimulation Therapy for Intermediate to Advanced Nonexudative Age-related Macular Degeneration (i-SIGHT2): a Multicentre, Randomised, Sham-controlled, Double-masked, Clinical Device Trial.

NCT06662162 is registered in ClinicalTrials.gov with i-Lumen Scientific AUS PTY LTD as lead sponsor.

NCT NCT06662162
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06662162 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Microcurrent Stimulation Therapy for Intermediate to Advanced Nonexudative Age-related Macular Degeneration (i-SIGHT2): a Multicentre, Randomised, Sham-controlled, Double-masked, Clinical Device Trial.
Lead sponsor
i-Lumen Scientific AUS PTY LTD
Phase
Not applicable
Overall status
Recruiting
Start date
May 7, 2025
Completion date
December 31, 2029
Enrollment
100 (estimated)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

age-related macular degeneration, age-related macular degeneration (armd), geographic atrophy secondary to age-related macular degeneration, intermediate amd